Uveal Melanoma - Pipeline Review, H1 2018

  • ID: 4521334
  • Drug Pipelines
  • 185 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb Co
  • Cleveland BioLabs Inc
  • Eli Lilly and Co
  • Immunocore Ltd
  • PEP-Therapy SAS
  • Plexxikon Inc
  • MORE
Uveal Melanoma - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Uveal Melanoma - Pipeline Review, H1 2018, provides an overview of the Uveal Melanoma (Oncology) pipeline landscape.

Uveal melanoma, the most common intraocular tumor, is a disease in which cancer (malignant) cells are found in the part of the eye called the uvea. The uvea contains cells called melanocytes. When these cells become cancerous, the cancer is called a melanoma. Symptoms include dark spot on the iris, glaucoma, eye pain and eye redness. Uveal melanoma is more common in people who have atypical mole syndrome, dysplastic nevus syndrome, and ocular or oculodermal melanocytosis. Treatment includes surgery, radiation and proton therapy.

Report Highlights:

This latest pipeline guide Uveal Melanoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Uveal Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveal Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Uveal Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 12, 10, 1 and 7 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Preclinical stages comprises 1, 1, 1 and 1 molecules, respectively.

Uveal Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Uveal Melanoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Uveal Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Uveal Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Uveal Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Uveal Melanoma (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Uveal Melanoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Uveal Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb Co
  • Cleveland BioLabs Inc
  • Eli Lilly and Co
  • Immunocore Ltd
  • PEP-Therapy SAS
  • Plexxikon Inc
  • MORE
Introduction

Report Coverage

Uveal Melanoma - Overview

Uveal Melanoma - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Uveal Melanoma - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Uveal Melanoma - Companies Involved in Therapeutics Development

Aeglea BioTherapeutics Inc

Bellicum Pharmaceuticals Inc

Bristol-Myers Squibb Co

Celldex Therapeutics Inc

Cleveland BioLabs Inc

Delcath Systems Inc

Eli Lilly and Co

Iconic Therapeutics Inc

Immunocore Ltd

Iovance Biotherapeutics Inc

Novartis AG

PEP-Therapy SAS

Pfizer Inc

Plexxikon Inc

Polaris Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Tesaro Inc

Viralytics Ltd

Uveal Melanoma - Drug Profiles

AU-011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPX-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cavatak - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Metastatic Uveal Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target GP100 for Melanoma and Non Small Cell Lung Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

crizotinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emibetuzumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

entinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

entolimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

galunisertib monohydrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glembatumumab vedotin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HDM-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HPH-196 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HPH-211 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ICON-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMCgp-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ipilimumab + nivolumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KCN-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LXS-196 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melphalan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

merestinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NAV-2729 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

niraparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pasireotide ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegargiminase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegzilarginase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEP-010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEP-020 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-2853 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sotrastaurin acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sunitinib malate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ulixertinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Uveal Melanoma - Dormant Projects

Uveal Melanoma - Discontinued Products

Uveal Melanoma - Product Development Milestones

Featured News & Press Releases

Jan 09, 2018: Positive Results From a Multi-Center Analysis of Delcath PHP Therapy Published in Journal of Surgical Oncology

Dec 11, 2017: Immunocores IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma

Dec 05, 2017: Favorable Results from a Multi-Center Analysis of Delcath PHP Therapy to be Published in Journal of Surgical Oncology

Nov 13, 2017: Immunocore Presents Single Agent IMCgp100 data in Metastatic Uveal Melanoma Showing Durability, Doubling in One-Year Overall Survival Rate

Oct 31, 2017: Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

Jun 05, 2017: Immunocore Announces Compelling Single Agent IMCgp100 Clinical Data in Metastatic Uveal Melanoma at ASCO 2017 Annual Meeting

Jun 01, 2017: Immunocore Highlights IMCgp100 clinical data in Uveal Melanoma at ASCO 2017 Annual Meeting

Nov 09, 2016: Immunocore Presents Positive Monotherapy Data in Uveal Melanoma at the Society for Melanoma Research (SMR) 2016 Congress

Apr 18, 2016: Celldex Therapeutics Presents data on Glembatumumab Vedotin at AACR 2

Mar 30, 2016: Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma

Jan 25, 2016: Immunocore’s IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma

Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC

Sep 09, 2015: Immunocore’s IMCgp100 Accepted for Adaptive Pathway Pilot Programme

Jun 29, 2015: Lilly and Immunocore To Conduct Phase Ib/II Clinical Trial Collaboration For Treatment Of uveal melanoma

May 22, 2015: Additional Tumor Type Cohorts Added to the Ongoing Phase 1 Study Combining ADI-PEG 20 with Cisplatin and Pemetrexed Based on New Research Results

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Uveal Melanoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Uveal Melanoma - Pipeline by Aeglea BioTherapeutics Inc, H1 2018

Uveal Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018

Uveal Melanoma - Pipeline by Bristol-Myers Squibb Co, H1 2018

Uveal Melanoma - Pipeline by Celldex Therapeutics Inc, H1 2018

Uveal Melanoma - Pipeline by Cleveland BioLabs Inc, H1 2018

Uveal Melanoma - Pipeline by Delcath Systems Inc, H1 2018

Uveal Melanoma - Pipeline by Eli Lilly and Co, H1 2018

Uveal Melanoma - Pipeline by Iconic Therapeutics Inc, H1 2018

Uveal Melanoma - Pipeline by Immunocore Ltd, H1 2018

Uveal Melanoma - Pipeline by Iovance Biotherapeutics Inc, H1 2018

Uveal Melanoma - Pipeline by Novartis AG, H1 2018

Uveal Melanoma - Pipeline by PEP-Therapy SAS, H1 2018

Uveal Melanoma - Pipeline by Pfizer Inc, H1 2018

Uveal Melanoma - Pipeline by Plexxikon Inc, H1 2018

Uveal Melanoma - Pipeline by Polaris Pharmaceuticals Inc, H1 2018

Uveal Melanoma - Pipeline by Syndax Pharmaceuticals Inc, H1 2018

Uveal Melanoma - Pipeline by Tesaro Inc, H1 2018

Uveal Melanoma - Pipeline by Viralytics Ltd, H1 2018

Uveal Melanoma - Dormant Projects, H1 2018

Uveal Melanoma - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Uveal Melanoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aeglea BioTherapeutics Inc
  • Bellicum Pharmaceuticals Inc
  • Bristol-Myers Squibb Co
  • Celldex Therapeutics Inc
  • Cleveland BioLabs Inc
  • Delcath Systems Inc
  • Eli Lilly and Co
  • Iconic Therapeutics Inc
  • Immunocore Ltd
  • Iovance Biotherapeutics Inc
  • Novartis AG
  • PEP-Therapy SAS
  • Pfizer Inc
  • Plexxikon Inc
  • Polaris Pharmaceuticals Inc
  • Syndax Pharmaceuticals Inc
  • Tesaro Inc
  • Viralytics Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll